David Andrew Long

This study constructs a cross-model spatial and single-cell atlas of PKD, identifying Spp1 (osteopontin) as a conserved driver of disease progression through its signaling to Ly6clo monocytes.

The paper develops an in silico framework to model human kidney haemodynamics using HiP-CT data, showing vascular geometry and resistance scaling influence kidney function.

The paper develops a low-cost method to create pre-vascularised scaffolds for organoid therapies, optimising parameters like porosity, lactide-to-glycolide ratio, and cell seeding density using PLGA and R-VECs.

The paper develops a nanobody-based method to label kidney lymphatic vessels in mice, revealing spatially restricted LYVE1 expression unique to the kidney.

This study shows vincristine treatment reduces podocyte damage in FSGS by preserving cytoskeletal structure and filtration barrier integrity.

This study identifies two progenitor sources for kidney lymphatics in mice: Tie2 endothelial lineage and Osr1 intermediate mesoderm, showing a dual origin for kidney lymphatic formation.

The paper identifies a unique pericystic endothelium in ADPKD that contributes to microvascular remodelling and impaired perfusion, suggesting vascular targets for early intervention.

This study investigates the role of elevated Gli3 in ARPKD and finds that reducing Gli3 levels does not affect cyst formation in mouse or human models.